Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents several concerns: declining revenue and increased net loss, reliance on milestone payments, and negative market sentiment in the TIGIT space. The Q&A section highlighted management's reluctance to provide details, adding uncertainty. Despite a solid cash balance, the financial outlook is weak, with decreased revenue and increased competition in the ovarian cancer treatment market. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Cash Balance $93.9 million as of June 30, 2025, with a cash runway expected to fund operations into 2027. This reflects a solid financial position.
Revenue $1.3 million for Q2 2025, a decrease from $6.7 million in Q2 2024. The decline is due to differences in milestone payments and upfront payments recognized from agreements with Gilead and AstraZeneca.
R&D Expenses $5.6 million for Q2 2025, a decrease from $6.2 million in Q2 2024. The reduction aligns with planned expenses.
G&A Expenses $2.2 million for both Q2 2025 and Q2 2024, showing no year-over-year change.
Net Loss $7.3 million for Q2 2025, compared to $2.1 million in Q2 2024. The increase in net loss is attributed to lower revenues in Q2 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
COM701: First patient dosed in MAIA-ovarian trial for platinum-sensitive ovarian cancer. Interim analysis expected in H2 2026. Aims to address unmet medical need with no standard of care for patients progressing post PARP inhibitors or bevacizumab.
rilvegostomig: AstraZeneca advancing rilvegostomig with potential commercial opportunity of over $5 billion in peak year revenues. Compugen eligible for milestone payments and royalties.
GS-0321: Phase I trial progressing as planned. Represents a novel approach to harness IL-18 pathway biology for cancer treatment.
TIGIT landscape: Potential for TIGIT antibodies to expand use in less inflamed PD-L1 low tumors. AstraZeneca advancing rilvegostomig in multiple trials, including Phase III.
Cash position: $93.9 million in cash as of June 2025, with expected runway into 2027.
Revenue: Q2 2025 revenue of $1.3 million, down from $6.7 million in Q2 2024 due to differences in milestone payments.
Leadership transition: Anat Cohen-Dayag transitioning to Executive Chair role, focusing on corporate strategy and collaborations. Eran Ophir to take over as CEO.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Increased competition in ovarian cancer treatment: The company faces increased competition in the platinum-resistant ovarian cancer treatment space, which could impact the market potential of its COM701 therapy.
Safety and efficacy challenges: In the maintenance setting for platinum-sensitive ovarian cancer, safety and efficacy are critical considerations, which could pose challenges in demonstrating the advantage of COM701.
Dependence on milestone payments and royalties: The company relies on milestone payments and royalties from partnerships with AstraZeneca and Gilead, which are subject to the success of their respective programs.
TIGIT program market sentiment: Failures in the TIGIT space have created negative market sentiment, which could impact the perception and potential of Compugen's TIGIT-related programs.
Revenue decline: Revenues for Q2 2025 were significantly lower compared to Q2 2024, reflecting a decline in milestone payments and upfront payments from partnerships.
Cash runway dependency: The company’s cash runway is dependent on no further cash inflows, which could limit its ability to fund operations beyond 2027 if additional funding is not secured.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
COM701 Clinical Development: The first patient was dosed in the MAIA-ovarian trial for platinum-sensitive ovarian cancer. Interim analysis from this sub-trial is expected in the second half of 2026. Positive data could support a broader clinical development program.
TIGIT Landscape and COM902: AstraZeneca is advancing rilvegostomig, a TIGIT bispecific derived from Compugen's COM902, with a potential commercial opportunity of over $5 billion in peak year revenues. Compugen is eligible for milestone payments and royalties. Successful Phase III data could validate TIGIT antibodies as a drug class and open new opportunities for Compugen.
GS-0321 Development: The Phase I trial for GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead, is progressing as planned.
Cash Runway and Financial Plans: The company has a cash runway expected to fund operations into 2027, supporting the COM701 trial, GS-0321 progression, and early-stage pipeline investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the patient enrollment dynamics for the platinum-sensitive ovarian cancer trial and the number of active sites?
A:The company has not disclosed the number of sites for the trial but has opened sites in the U.S. and Israel. They are actively enrolling patients with high investigator enthusiasm and are working to meet aggressive timelines.
Q:What should investors focus on in the ESMO presentation, and will it include biomarker data analysis?
A:The presentation will focus on understanding the efficacy and safety of patients who responded in prior studies through pooled data analysis. More details will be presented during ESMO.
Q:What can we expect from the TROPION-PanTumor 03 data in bladder cancer, and what is the potential for further development?
A:AstraZeneca has not provided guidance on what will be presented at ESMO for this study. The data in bladder cancer will involve a combination with ADC, and the company is also awaiting the results.
Q:What is the market opportunity in the platinum-sensitive maintenance setting for ovarian cancer?
A:The initial opportunity is for second- and third-line patients requiring maintenance, approximately 8,000 to 12,000 patients. If single-agent COM701 works in maintenance, it could open avenues for broader ovarian cancer patient populations.
Q:What are your expectations from Merck's successful Phase III in ovarian cancer, and how does it change your approach?
A:Merck's study demonstrated PFS and overall survival advantages in platinum-resistant patients. While it provides hints of activity in earlier lines, it does not change the company's approach as their focus is on platinum-sensitive patients.
Q:Can you provide insights into the pipeline and when we may expect details?
A:The company is using its Unigen platform to develop more assets but prefers not to disclose details for competitive reasons. Work is ongoing to bring more assets in immuno-oncology.
Q:Can you provide more details on the interim analysis planned for the global maintenance ovarian study in the second half of 2026?
A:The study is an adaptive trial design aiming for a 3-month improvement. The interim analysis will evaluate futility and characterize the effect size of COM701. The study is expected to be fully enrolled by then.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of sites for the platinum-sensitive ovarian cancer trial and AstraZeneca's guidance on the TROPION-PanTumor 03 data. They also refrained from disclosing pipeline details for competitive reasons.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC Dato
AI ML
Anat Cohen
Anat welcome
AstraZeneca rilvegostomig
AstraZeneca risk
AstraZeneca term
AstraZeneca trial
CEO President
CEO prouder
COM Clinically
COM addition
COM monotherapy
Chief Scientific
Cohen Dayag
Dato DXd
Dr Chief
ESMO
Officer Chief
Officer Dr
Phase III
QA
Scientific Officer
Silberman Chief
approach
cancer combination
mechanism action
need
oncology
protein
response
space
system cancer
treatment option
trial rilvegostomig
CGEN Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Unknown5-18
The earnings call summary presents a mixed picture. On one hand, there is a 15% revenue increase and a 10% improvement in net loss, which are positive indicators. However, the lack of discussion on operational updates and strategic initiatives, coupled with risks related to cash management and clinical timelines, introduces uncertainty. The neutral sentiment reflects the balance between financial performance improvements and potential risks, with no strong catalysts to drive a significant stock price change.
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call reveals strong financial performance, with significant revenue growth and a net profit turnaround due to strategic partnerships with AstraZeneca and Gilead. The cash runway supports ongoing projects, and milestone payments are lined up. Despite some uncertainties in timelines, the strategic partnerships and potential in the oncology field are promising. Analysts' questions highlight interest in future milestones and expansions, suggesting confidence in the company's direction. The positive financial results and strategic developments suggest a positive impact on stock price.
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call reveals significant challenges: declining revenues, a shift from profit to loss, and reliance on partnerships and milestone payments. Safety concerns with anti-TIGIT antibodies and competition in the market add risks. The Q&A section highlights uncertainties in trial timelines and outcomes, further dampening sentiment. Despite potential opportunities with COM902 and a cash runway until 2027, the overall financial and strategic outlook suggests a negative market reaction.
Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents several concerns: declining revenue and increased net loss, reliance on milestone payments, and negative market sentiment in the TIGIT space. The Q&A section highlighted management's reluctance to provide details, adding uncertainty. Despite a solid cash balance, the financial outlook is weak, with decreased revenue and increased competition in the ovarian cancer treatment market. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
CGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
